Teichmann Sarah A. 4

What Happened
Sarah A. Teichmann, a director of 10x Genomics, sold 7,579 shares of TXG common stock in an open-market transaction on February 25, 2026. The shares were sold at $19.41 per share for gross proceeds of $147,108. This was a sale (not a purchase or grant), typically a routine disposition of shares rather than a direct bullish signal.

Key Details

• Transaction date and price: 2026-02-25, 7,579 shares at $19.41 each (total $147,108).
• Transaction type: Sale (code S) reported as an open-market or private sale.
• Shares owned after transaction: Not specified in the excerpt provided—see the filed Form 4 for post-transaction beneficial ownership.
• Footnote: Sale was effected pursuant to the reporting person’s Rule 10b5-1 trading plan adopted November 26, 2025.
• Filing/Timing: Form 4 was filed on 2026-02-27 for a 2026-02-25 transaction; this appears to be filed within the normal two-business-day window.
• Additional exhibit: Exhibit 24.1 (Power of Attorney) is attached to the filing.

Context
Sales executed under a Rule 10b5-1 plan are pre-arranged trading programs that allow insiders to sell shares according to a preset schedule or parameters; such sales are often routine and do not necessarily reflect the insider’s current view of the company. For retail investors, a single director sale of this size is informational but not by itself a clear indicator of company prospects—look for patterns of multiple insider buys or sells, and combine with company fundamentals and news.